Annovis Bio To Continue Alzheimer's Disease Clinical Trials [Seeking Alpha]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Seeking Alpha
Follow Play 8min Summary In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70% stock drop. The company plans to proceed with a phase 3 trial despite the lack of convincing efficacy data and significant financial constraints. Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain. We Are Introduction Annovis Bio is a small biotech company focused on neurodegenerative disorders. Initially, we anticipated covering this stock three times—prior to Alzheimer's Disease (AD) and Parkinson's Disease (PD) data, post-AD data, and post-PD data. However, this article marks the third follow-up to our original article on Annovis from January 2024, and the stock is down approximately 40% since then. This update will be brief and will provide an overview of the facts, as we see them, since our initial coverage, particularly regardi
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)GlobeNewswire
- Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Annovis Bio Reports Third Quarter Financial Results and Provides Business UpdateGlobeNewswire
- Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical ScientistGlobeNewswire
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis BioGlobeNewswire
ANVS
Earnings
- 11/11/24 - Beat
ANVS
Sec Filings
- 11/12/24 - Form 8-K
- 11/8/24 - Form 10-Q
- 10/15/24 - Form 8-K
- ANVS's page on the SEC website